State Street’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

State Street’s Portfolio KBIO Stock Details KBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-12,201	Closed	-$266K	–	3748
2014 Q1	$266K	Buy	12,201 +603	+5%	+$17.5K	﹤0.01%	3429
2013 Q4	$411K	Sell	11,598 -217	-2%	-$7.27K	﹤0.01%	3382
2013 Q3	$427K	Sell	11,815 -62	-0.5%	-$2.82K	﹤0.01%	3366
2013 Q2	$538K	Buy	+11,877	New	+$539K	﹤0.01%	3239

Other funds holding KBIO

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

State Street's KBIO Position: Q2 2014 in Review

State Street sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q2 2014, closing a stake of 12,201 shares — an estimated $266K sold.

State Street first reported a position in KBIO in Q2 2013 and held it in 4 quarters. The position peaked at $538K in Q2 2013. 43 funds tracked by Wall St. Rank hold KBIO as of Q2 2014.

State Street reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q2 2014 after selling out during the quarter.
State Street sold 12,201 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q2 2014, an estimated $266K.
State Street first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 4 quarters.
State Street's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $538K in Q2 2013.
43 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q2 2014.

Based on State Street's 13F filing for Q2 2014, filed 12 Aug 2014.